|
| |
Outsourcing in Drug Development: The Contract Research (Clinical Trial ) Market
|
Published: Jan 2012 | Pages: 235 | Pub ID: MM1325826548 |
|
|
|
 |
The cost and time of developing and bringing a drug to market is over $1.3 billion and often takes as long as 15 years, if not longer. Because of this, major pharmaceutical marketers continue to outsource stages of development, and over the years Kalorama Information has observed this process. In past editions of our outsourcing market studies, we found that outsourcing moved from "should" to "must." for manufacturers. This trend has only continued in the past two years.
Contract Research Organizations (CROs) and other entities can expect growing demand for their services. The demand for new drugs remains unabated, but the cost and need to bring those drugs to market is ever-increasing and intensifying. A key cost driver is the large number of failures during the expensive clinical trial phases. Driven by pressures to reduce costs, companies are increasingly implementing outsourcing strategies to increase revenues through faster drug development. By decreasing their in-house facilities and staff, and outsourcing more of their R&D functions, pharmaceutical and biotechnology companies are reshaping the drug development services industry.
Kalorama Information\'s Outsourcing in Drug Development: The Contract Research (Clinical Trial) Market is the third edition of this study of the drivers for outsourcing drug development, the companies involved in this market and the opportunity for revenues. As part of its comprehensive coverage of this market, this report contains:
- A Detailed Introduction to the Clinical Trial Process
- Statistics of Drugs in Development by Phase
- Market Size and Forecasts for Outsourcing In Drug Development by Academic Medical Center (AMC), Contract Research Organizations and Others.
- Main Drivers for Outsourcing in Drug Development
- How CROs are Meeting the Challenge of Patient Recruitment
- Discussion of Industry and Regulatory TrendsProtocols Funded in FY2009 by Percent and Gender
- Global R&D Expenditures Outsourced by Percent 2003-2010
- Selected Pharmaceutical Company Acquisitions, 2009-2011
- Top Ten Therapeutic Categories in R&D
- Selected Acquisitions of Leading CROs
- Increasing role of EDCs
- Globalization Trends in Drug Development and Breakout of Clinical Trials by Region
- Directory of Companies
- Market Share of Major CROs 2011
- Profiles of CROs, Contract Laboratories, Clinical Trial Labs and EDC Solution Companies
|
|
| By: Kalorama Information |
|
|
| |
|
|
|
US Office
India Office